By Chris Wack
60 Degrees Pharmaceuticals has announced its plans to move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S. This decision was made following a Type C meeting with the Food and Drug Administration (FDA) on Wednesday.
To prepare for the meeting, 60 Degrees Pharmaceuticals provided the FDA with an information package. The package detailed the unmet medical need for a new therapeutic for hospitalized babesiosis patients and included a comprehensive outline of the proposed study protocol.
During the meeting, the FDA expressed that the proposed study could potentially meet regulatory approval if a clinical endpoint is used instead of a surrogate marker. Taking this feedback into consideration, 60 Degrees Pharmaceuticals is currently revising its study protocol and aims to begin patient enrollment in the summer of 2024.
It's important to note that while tafenoquine is approved for malaria prophylaxis in patients 18 years and older, it has not been proven effective in treating or preventing babesiosis. The FDA has yet to approve tafenoquine for this particular indication.
Fund 1 Investments Raises Stake in Tilly's
Related Articles
Elon Musk's Visit to Israel
Elon Musk is heading to Israel to address the fallout from a controversial tweet that has been condemned as anti-Semitic. This article discusses the meeting, th...
Fisker Inc. Enhances Service Capabilities, Shares Rally
Fisker Inc. improves service capabilities, expands repair network, and rolls out over-the-air updates for enhanced vehicle performance. Shares rally after a rec...
SAP's Job-Cutting Plan and Profit Boost
SAP plans to cut jobs and improve profits, leading to an 8% jump in shares. Impressive Q4 earnings and strong cloud backlog contribute to positive market perfor...